CVS Health Corporation provides health solutions in the United States. The company operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare Supplement plans, PDPS and Medicaid health care management services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Health Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, specialty and mail order pharmacy, clinical, disease management, medical spend management services, pharmacy and other administrative services. It serves employers, insurance companies, unions, government employee groups, health plans, PDPS, Medicaid managed care plans, CMS, plans offered on public health insurance, and other sponsors of health benefit plans. The Pharmacy & Consumer Wellness segment sells prescription and over-the-counter drugs, consumer health and beauty products, personal care products, and other general merchandise products. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. It operates online retail pharmacy websites, retail specialty pharmacy stores, compounding pharmacies and branches for infusion and enteral nutrition services. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1963 and is headquartered in Woonsocket, Rhode Island.
| Business Activity | PASS |
| Debt Ratio (0.32%) | PASS |
| Cash Ratio (0.11%) | PASS |
| Receivables Ratio (0.10%) | PASS |
| Revenue Ratio (0.00%) | PASS |
| Overall | PASS |
| Date | EPS Est. | Reported EPS | Surprise % |
|---|---|---|---|
| 2026-07-30 | 1.82 | Pending | -- |
| 2026-05-06 | 2.21 | 2.57 | +16.5% |
| 2026-02-10 | 1.00 | 1.09 | +9.4% |
| 2025-10-29 | 1.36 | 1.60 | +17.9% |
| 2025-07-31 | 1.46 | 1.81 | +23.9% |
| 2025-05-01 | 1.28 | 1.41 | +10.5% |
| 2025-02-12 | 0.92 | 1.19 | +29.6% |
| 2024-11-06 | 1.31 | 0.07 | -94.7% |
| Period | Revenue | Net Income | EBITDA | Gross Profit | Op. Income | EPS |
|---|---|---|---|---|---|---|
| 2026-03-31 | $100.4B | $2.9B | $5.8B | $15.6B | $4.7B | 2.31 |
| 2025-12-31 | $105.7B | $2.9B | $3.3B | $13.6B | $2.1B | 2.32 |
| 2025-09-30 | $102.9B | -$4.0B | -$1.6B | $13.8B | $2.5B | -3.13 |
| 2025-06-30 | $98.9B | $1.0B | $3.6B | $13.6B | $2.4B | 0.81 |
| 2025-03-31 | $94.6B | $1.8B | $4.6B | $14.4B | $3.4B | 1.41 |
| 2024-12-31 | — | — | — | — | — | — |
| Date | Name | Role | Shares | Value |
|---|---|---|---|---|
| 2026-05-21 | ROBBINS LARRY | Director | 3,372,000 | $317.5M |
| 2026-05-14 | NORWALK LESLIE V | Director | 1,447 | $140.6K |
| 2026-05-14 | BALSER JEFFREY R M.D., PH.D. | Director | 2,058 | $199.9K |
| 2026-05-14 | SANSONE GUY P | Director | 1,447 | $140.6K |
| 2026-05-14 | AGUIRRE FERNANDO | Director | 1,563 | $151.8K |
| 2026-05-14 | BROWN C DAVID II | Director | 1,544 | $150.0K |
| 2026-05-14 | KIRBY JOHN SCOTT | Director | 1,447 | $140.6K |
| 2026-05-08 | MANDADI TILAK | Officer | 69,551 | $6.2M |
| 2026-03-31 | KHICHI SAMRAT S | General Counsel | 12,531 | $900.0K |
| 2026-03-31 | CAPOZZI HEIDI B | Officer | 10,025 | $720.0K |
| Holder | Shares | Value | % Held |
|---|---|---|---|
| Blackrock Inc. | 125.9M | $11.7B | 0.1% |
| Vanguard Capital Management LLC | 82.7M | $7.7B | 0.1% |
| Capital World Investors | 77.2M | $7.2B | 0.1% |
| State Street Corporation | 59.3M | $5.5B | 0.0% |
| Dodge & Cox Inc. | 51.8M | $4.8B | 0.0% |
| FMR, LLC | 31.2M | $2.9B | 0.0% |
| JPMORGAN CHASE & CO | 29.5M | $2.8B | 0.0% |
| Geode Capital Management, LLC | 29.5M | $2.7B | 0.0% |
| Vanguard Portfolio Management LLC | 26.0M | $2.4B | 0.0% |
| Invesco Ltd. | 25.1M | $2.3B | 0.0% |
$185.7B
1.53
0.592
26
$405.6B
$78.3B
+63.1%
2.7%
1.50
2.36
0.0%
219,000
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| 2026-07-30 | $1.82 | Pending | — |
| 2026-05-06 | $2.21 | $2.57 | +16.5% |
| 2026-02-10 | $1.00 | $1.09 | +9.4% |
| 2025-10-29 | $1.36 | $1.60 | +17.9% |
| 2025-07-31 | $1.46 | $1.81 | +23.9% |
| 2025-05-01 | $1.28 | $1.41 | +10.5% |
| Shares | Cost | Profit to Target | R:R |
|---|---|---|---|
| To Consensus ($101.88, 26 analysts) | |||
| 10 | $905.50 | +$113.30 (13%) | 0.8R |
| 50 | $4,527.50 | +$566.50 (13%) | 0.8R |
| 100 | $9,055.00 | +$1,133.00 (13%) | 0.8R |
| To Fair Value ($100.35) | |||
| 10 | $905.50 | +$98.00 (11%) | 0.7R |
| 50 | $4,527.50 | +$490.00 (11%) | 0.7R |
| 100 | $9,055.00 | +$980.00 (11%) | 0.7R |
- No elevated risk flags in current data
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| HUM | 0.502 |
| UNH | 0.493 |
| ELV | 0.484 |
| CI | 0.447 |
| ALHC | 0.352 |
| Ticker | Correlation |
|---|---|
| CINECO.BH | -0.162 |
| HACBY | -0.161 |
| 4326.SR | -0.161 |
| ZHCD.QA | -0.140 |
| PANSAR.KL | -0.125 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
After this company beats earnings, does the price keep going up? Drift tracks post-earnings momentum.
How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.